Flamingo Therapeutics Announces First Patient Dosed in Investigator-Initiated Trial (IIT) Evaluating Danvatirsen in Phase 1 for AML/MDS Cancers

Flamingo Therapeutics (“Flamingo”) today announced that the first patient has been dosed in an Investigator-initiated Trial (IIT) evaluating the safety and efficacy of danvatirsen in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who have relapsed or are refractory to frontline therapy.

Go to Top